Literature DB >> 27512946

In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury.

Sidonia Mihai1,2, Heike Albert1, Ralf J Ludwig3, Hiroaki Iwata3, Lars Björck4, Mattias Collin4, Falk Nimmerjahn1.   

Abstract

IgG antibodies are potent inducers of proinflammatory responses by cross-linking Fc receptors on innate immune effector cells resulting in tissue injury. The recently discovered enzymes endoglycosidase S (EndoS) and IgG-degrading enzyme (IdeS) of Streptococcus pyogenes are able to modulate the interaction between IgG antibodies and the Fc receptors, by hydrolysis of the glycan associated with the heavy chain of the IgG molecule (EndoS), or cleavage in the hinge region of the heavy IgG chain (IdeS). In this work, we investigated their ability to inhibit damage mediated by skin-bound antibodies in vivo in two different experimental models, the Arthus reaction, and epidermolysis bullosa acquisita, an autoimmune blistering skin disease associated with autoantibodies against type VII collagen. We demonstrate that both enzymes efficiently interfere with IgG-mediated proinflammatory processes, offering a great asset to specifically target pathological IgG antibodies in the skin and holding great promise for future applications in human therapy.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EndoS; IdeS; immunoglobulin G; immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27512946     DOI: 10.1111/exd.13163

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

Review 1.  Structural insights into the mechanisms and specificities of IgG-active endoglycosidases.

Authors:  Jonathan J Du; Erik H Klontz; Marcelo E Guerin; Beatriz Trastoy; Eric J Sundberg
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

Review 2.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

3.  Molecular Basis of Broad Spectrum N-Glycan Specificity and Processing of Therapeutic IgG Monoclonal Antibodies by Endoglycosidase S2.

Authors:  Erik H Klontz; Beatriz Trastoy; Daniel Deredge; James K Fields; Chao Li; Jared Orwenyo; Alberto Marina; Robert Beadenkopf; Sebastian Günther; Jair Flores; Patrick L Wintrode; Lai-Xi Wang; Marcelo E Guerin; Eric J Sundberg
Journal:  ACS Cent Sci       Date:  2019-02-06       Impact factor: 14.553

4.  Immunoglobulin G Glycoprofiles are Unaffected by Common Bottom-Up Sample Processing.

Authors:  Manuela Amez-Martín; Manfred Wuhrer; David Falck
Journal:  J Proteome Res       Date:  2020-09-18       Impact factor: 4.466

5.  Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme.

Authors:  Zachary C Elmore; Daniel K Oh; Katherine E Simon; Marco M Fanous; Aravind Asokan
Journal:  JCI Insight       Date:  2020-09-17

Review 6.  Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease.

Authors:  Rachel E Crossland; Francesca Perutelli; Katarzyna Bogunia-Kubik; Nuala Mooney; Nina Milutin Gašperov; Maja Pučić-Baković; Hildegard Greinix; Daniela Weber; Ernst Holler; Dražen Pulanić; Daniel Wolff; Anne M Dickinson; Marit Inngjerdingen; Magdalena Grce
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.